克瘤丸对晚期非小细胞肺癌血清VEGF水平的影响

The Effect of KELIUWAN on Serum VEGF of Advanced Non -small- cell Lung Cancer

[目的]探讨克瘤丸对晚期非小细胞肺癌血清VEGF的影响。[方法]将符合纳入标准的患者随机分为A组41例、B组40例、C组40例，A组采用克瘤丸治疗，B组采用NP或GP方案治疗，C组采用克瘤丸联合化疗治疗，观察治疗前后患者的瘤体大小、血清血管内皮生长因子（VEGF）水平的变化。[结果]疾病控制率C组高于A组、B组，差异有统计学意义（P〈0．05）；A组、C组治疗前后VEGF值变化差异有统计学意义（P〈0．05）；在获得PR、SD的患者中，A组、C组治疗后VEGF值明显下降，与治疗前比较，差异有统计学意义（P〈0．05）。[结论]克瘤丸与化疗联合治疗非小细胞肺癌能显著提高疾病的控制率；单药克瘤丸、克瘤丸与化疗联合可在一定程度上降低血清VEGF水平，且显示出与临床客观疗效有一定的相关性。

[ Objective] To explore the effect of KELIUWAN on serum VEGF of advanced non - small - cell lung cancer. [ Method] The patients who were consistent with standard were randomly divided into three groups ： group A （KELIUWAN） ; group B （chemotherapy） ; group C （chemotherapy combined with KELIUWAN）. The tumor size and serum VEGF before and after treatment were observed. [ Results ] Disease control rate of group C was higher than group A and B, and the difference had statistical significance（P 〈0.05） ; the VEGF value differences before and after treatment in group A and C has statistical significance（ P 〈0.05 ）. In patients achieved PR and SD, the VEGF value in group A and C declined remarkably compared with before treatment, which has statistical significance （P 〈 0.05 ）. [ Conclusions] KELIUWAN combined with chemotherapy could remarkably enhanced the control rate of disease. Both of single drug KELIUWAN or KELIUWAN combined with chemotherapy could reduce the serum VEGF level to some extent, indicating certain relativity with objective clinical curative effects.